Natera Reports Preliminary Q4 2025 Results, Record Year for Oncology Testing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Businesswire
- Strong Performance: Natera anticipates a record year in 2025 for oncology, organ health, and women’s health, with particularly robust growth in Q4, indicating the company's strong performance in precision medicine.
- Growth Drivers: CEO Steve Chapman highlighted excellent growth in revenue and gross margins during Q4, showcasing the company's competitive position and potential for sustained growth in the market.
- Future Outlook: Natera plans to leverage this momentum into 2026, expecting to further drive business expansion and market share, particularly in the personalized genetic testing sector.
- Investor Communication: The company will release complete financial results during its earnings call in February 2026 and provide additional business updates at the J.P. Morgan Healthcare Conference in January, enhancing engagement with investors.
Analyst Views on NTRA
Wall Street analysts forecast NTRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRA is 233.50 USD with a low forecast of 172.00 USD and a high forecast of 280.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 239.560
Low
172.00
Averages
233.50
High
280.00
Current: 239.560
Low
172.00
Averages
233.50
High
280.00
About NTRA
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
